In multiple sclerosis, a central nervous system inflammatory demyelinating disease, PKCβ inhibitors can stabilize the blood–brain barrier by targeting PKCβ in endothelial cells and possibly astrocytes, thereby inhibiting disease progression (37). Here, PRKCB is linked to demyelinating disease.